UBE2NUBE2V2

UBE2N and UBE2V2 encode two closely related ubiquitin-conjugating enzymes (E2s) that function as a heterodimeric complex in the ubiquitin system. Both proteins belong to the ubiquitin-conjugating enzyme family and contain the conserved active site cysteine required for thioester bond formation with ubiquitin. UBE2N (also known as UBC13) and UBE2V2 (UBC-V2) are typically expressed in human tissues such as liver, kidney, brain and immune cells. Gene loci are located on chromosome 6p21.1 for UBE2N and chromosome 18q12.1 for UBE2V2.

The UBE2N/UBE2V2 complex is essential for catalyzing K63-linked polyubiquitin chains, a linkage type that primarily regulates signaling pathways rather than targeting proteins for proteasomal degradation. Formation of the heterodimer occurs via a non-covalent interaction between the UBE2N catalytic domain and the variant V2 protein, which lacks catalytic cysteine but stabilizes substrate recognition and chain elongation. This complex is involved in DNA damage response, NF‑κB activation, innate immune signaling, and cell cycle control.

Dysregulation of the UBE2N/UBE2V2 system has been associated with various pathological conditions. Elevated UBE2N activity contributes to inflammatory disorders, certain cancers, and viral replication, whereas decreased activity can impair DNA repair and immune responses. Genetic variants or altered expression levels of these genes are reported in chronic lymphocytic leukemia, colorectal cancer, and neurodegenerative diseases.

Experimental studies demonstrate that knockout or knockdown of UBE2N or UBE2V2 in cell lines or animal models leads to reduced K63-linked ubiquitination, diminished NF‑κB signaling, and increased sensitivity to DNA damage. Small-molecule inhibitors targeting the UBE2N/UBE2V2 interface are in early development as potential therapeutic agents for inflammatory and malignant diseases.